Featured Press Releases

Spencer Trask & Co. launches Signal12 for Dry Eye Disease treatment, led by former Aerie executives, advancing Pro-ocular through trials

Spencer Trask & Co. launches Signal12 for Dry Eye Disease treatment, led by former Aerie executives, advancing Pro-ocular through trials

Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington

Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

  • 30 Jun 2025

Neurocrine Biosciences, Inc. announced new patient-reported post-hoc data from the KINECT®-HD...

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Distinct Payloads to Address Limitations of Current ADCs

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Distinct Payloads to Address Limitations of Current ADCs

Tiger BioSciences Launched carePAC™: Pre-Configured Wound Care Kits for Simplified At-Home Management

Tiger BioSciences Launched carePAC™: Pre-Configured Wound Care Kits for Simplified At-Home Management

SK bioscience Improves Vaccine Access by Securing Its First UNICEF Procurement Contract

SK bioscience Improves Vaccine Access by Securing Its First UNICEF Procurement Contract

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

  • Abbott
  • 26 Aug 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

  • Jazz Pharmaceuticals plc
  • 25 Aug 2026
European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

  • Acadia Pharmaceuticals Inc.
  • 24 Aug 2026
Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

  • Upsher-Smith Laboratories, LLC
  • 21 Aug 2026
Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

  • Dunbar Pharmaceuticals
  • 18 Aug 2026
Former DePuy Synthes U.S. President Joins Peptilogics Board

Former DePuy Synthes U.S. President Joins Peptilogics Board

  • Peptilogics
  • 18 Aug 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.